This report was first published by Endpoints News. To see the original version, click here
Two years ago, CRISPR gene editing pioneer Feng Zhang and former Illumina chief technology officer Alex Aravanis launched a startup to develop medicines that would change how genes are turned on and off without altering DNA itself.
That company, Moonwalk Biosciences, was expected to become a major contender in the growing field of epigenetic editing. But now Moonwalk has dropped its original plans and pivoted to a more established class of genetic medicines known as siRNAs, Endpoints News has learned.
您已阅读13%（595字），剩余87%（3881字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。